Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
Total article views | Abstract views | HTML views | PDF downloads | Totals | |
---|---|---|---|---|---|
17,762 | Dovepress* | 7,451 | 2,929+ | 1,767 | 10,380 |
PubMed Central* | 0 | 7,382 | 1,354 | 7,382 | |
Totals | 7,451 | 10,311 | 3,121 | 17,762 | |
*Since 31 May 2018 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 0 | 0 | 0 | 1 | 1 |
View citations on PubMed Central and Google Scholar